• Marit Ahrens, Arndt Hartmann, and Lothar Bergmann.
• Medizinische Klinik 2, Hämatologie und Onkologie, Universitätsklinikum der Johann-Wolfgang-Goethe-Universität Frankfurt, Frankfurt am Main.
• Dtsch. Med. Wochenschr. 2020 Jun 1; 145 (11): 734-739.

AbstractRenal cell carcinomas (RCC) include different tumor entities, of which clear cell RCC is the most common tumor with approx. 75 % followed by the papillary RCC with 10-15 %. RCC are increasingly being diagnosed incidental in the context of abdominal diagnostics from other indications using sonography or cross-sectional imaging.The prognosis of metastatic RCC has improved significantly due to new therapy options, especially through the use of immune checkpoint inhibitors (IO). In the first line, combination therapies of the tyrosine kinase inhibitor (TKI) axitinib with the PD-1 antibody pembrolizumab or the PDL-1 antibody avelumab apply regardless of the risk profile and histological entity, as well as the combination of the CTLA4 antibody ipilimumab with the PD-1 antibody nivolumab in patients with intermediate and high risk as new standards in therapy. The combinations lead to a higher response rate and longer survival. In the second line and subsequent lines, there is no evidence-based data after combination therapies, but drugs can be used that were not yet part of the first-line therapy.© Georg Thieme Verlag KG Stuttgart · New York.

15 keywords...

hide…